Home » EMEA Committee for Orphan Medicinal Products Recommends Orphan Medicinal Product Designation for Lux Biosciences’ LX211 for the Treatment of Uveitis
EMEA Committee for Orphan Medicinal Products Recommends Orphan Medicinal Product Designation for Lux Biosciences’ LX211 for the Treatment of Uveitis
Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced that the EMEA committee for Orphan Medicinal Products has adopted a positive opinion on orphan medicinal product designation for the company’s investigational therapeutic, LX211, for the treatment of chronic, non-infectious uveitis.
BusinessWire
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May